There are 2789 resources available
770P - Wild-type BRCA1/2 ovarian cancer: Prospective follow-up data from a multidisciplinary program
Presenter: Inês Oliveira
Session: ePoster Display
771P - Mutational landscape and clonal evolution of coexisting ovarian cancer and borderline tumor
Presenter: Lei Li
Session: ePoster Display
772P - Hormonal therapy in pretreated patients with metastatic or refractory ovary granulosa cell tumor
Presenter: Izzet Dogan
Session: ePoster Display
773P - Prognostic value of preoperative soluble interleukin 2 receptor α as a novel immune biomarker in epithelial ovarian cancer
Presenter: Hui Li
Session: ePoster Display
774P - Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial
Presenter: Qin Xu
Session: ePoster Display
775P - Tremelimumab (T) + durvalumab (D) combined with metronomic oral vinorelbine (MOV): Results of the recurrent cervical cancer (RCC) cohort of the MOVIE study
Presenter: Jean-Sebastien Frenel
Session: ePoster Display
776P - SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for pretreated advanced cervical cancer: Data from a clinical expansion cohort of a phase I study
Presenter: Jifeng Feng
Session: ePoster Display
777P - A prospective, single-arm, open-label study of camrelizumab, apatinib and nab-paclitaxel in patients with advanced cervical cancer
Presenter: guiling Li
Session: ePoster Display
778P - BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer
Presenter: Giorgio Bogani
Session: ePoster Display
779P - Metronomic low-dose capecitabine in metastatic, recurrent or persistent carcinoma of cervix as 3rd line and beyond
Presenter: Irappa Madabhavi
Session: ePoster Display